<DOC>
	<DOCNO>NCT02465515</DOCNO>
	<brief_summary>Albiglutide analogue glucagon-like peptide-1 ( GLP-1 ) , use treat type 2 diabetes This study test whether albiglutide affect occurrence major cardiovascular event heart attack stroke important medical outcome person type 2 diabetes , use alone added diabetes treatment .</brief_summary>
	<brief_title>Effect Albiglutide , When Added Standard Blood Glucose Lowering Therapies , Major Cardiovascular Events Subjects With Type 2 Diabetes Mellitus</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>rGLP-1 protein</mesh_term>
	<mesh_term>Glucagon-Like Peptide 1</mesh_term>
	<criteria>Men woman least 40 year old . Women must postmenopausal use highly effective method avoidance pregnancy . Diagnosis type 2 diabetes . Established cardiovascular disease least one following : coronary artery disease , cerebrovascular disease , peripheral arterial disease . HbA1c &gt; 7.0 % ( 53 mmol/mol ) ( base recent documented laboratory measurement within 6 month ) . Able willing provide inform consent . Severely reduced kidney function : eGFR &lt; 30 ml/min/1.73 m^2 ( base last measured document laboratory measurement within 6 month ) renal replacement therapy . Use GLP1 receptor agonist Screening . Severe gastroparesis History pancreatitis consider clinically significant risk develop pancreatitis course study . Personal family history medullary carcinoma thyroid subject multiple endocrine neoplasia type 2 ( MEN2 ) . Personal history pancreatic neuroendocrine tumour . Medical history might limit subject 's ability take trial treatment duration study otherwise complete study . Breastfeeding , pregnancy , plan pregnancy course study . Note : pregnancy test perform woman child bear potential prior study entry . Known allergy GLP1 receptor agonist excipients albiglutide . Use another investigational product within 30 day accord local regulation , currently enrol study investigational device . Any reason investigator deems subject unsuitable study .</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2017</verification_date>
	<keyword>cardiovascular event /outcomes</keyword>
	<keyword>Type 2 diabetes mellitus</keyword>
	<keyword>albiglutide</keyword>
	<keyword>glucagon-like peptide-1 receptor agonist</keyword>
</DOC>